Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
<,11417445,S/R ratio,Six extensive (mephenytoin S/R ratio < 0.3; EM) and six poor (mephenytoin S/R ratio > 0.8; PM) hydroxylators of S-mephenytoin ingested a single 10-mg oral dose of selegiline hydrochloride.,CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417445/),,0.3,12075,DB01037,Selegiline
>,11417445,S/R ratio,Six extensive (mephenytoin S/R ratio < 0.3; EM) and six poor (mephenytoin S/R ratio > 0.8; PM) hydroxylators of S-mephenytoin ingested a single 10-mg oral dose of selegiline hydrochloride.,CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417445/),,0.8,12076,DB01037,Selegiline
,8785378,half-life,A half-life of approximately 70 min was observed following the administration of either dosage form.,Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785378/),min,70,40112,DB01037,Selegiline
,14628189,area-under-the curve (AUC(0- infinity)),Mean [SD] area-under-the curve (AUC(0- infinity)) values following Zydis Selegiline 10 mg (5.85 [7.31] ng.h/mL) were approximately five times higher than those following conventional selegiline tablets 10 mg (1.16 [1.05] ng.h/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[h·ng] / [ml],5.85,41070,DB01037,Selegiline
,14628189,area-under-the curve (AUC(0- infinity)),Mean [SD] area-under-the curve (AUC(0- infinity)) values following Zydis Selegiline 10 mg (5.85 [7.31] ng.h/mL) were approximately five times higher than those following conventional selegiline tablets 10 mg (1.16 [1.05] ng.h/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[h·ng] / [ml],1.16,41071,DB01037,Selegiline
,14628189,C(max),The C(max) of selegiline was similar following administration of Zydis Selegiline 1.25 mg (1.52 ng/mL) or conventional selegiline tablets 10 mg (1.14 mg/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],1.52,41072,DB01037,Selegiline
,14628189,C(max),The C(max) of selegiline was similar following administration of Zydis Selegiline 1.25 mg (1.52 ng/mL) or conventional selegiline tablets 10 mg (1.14 mg/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[mg] / [ml],1.14,41073,DB01037,Selegiline
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],1.19,41074,DB01037,Selegiline
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],0.34,41075,DB01037,Selegiline
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],0.93,41076,DB01037,Selegiline
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],18.37,41077,DB01037,Selegiline
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],3.60,41078,DB01037,Selegiline
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],12.92,41079,DB01037,Selegiline
,14628189,excretion,Mean daily PEA excretion was similar following Zydis Selegiline 1.25 mg and conventional selegiline tablets 10 mg (13.0 microg versus 17.6 microg).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),μg,13.0,41080,DB01037,Selegiline
,14628189,excretion,Mean daily PEA excretion was similar following Zydis Selegiline 1.25 mg and conventional selegiline tablets 10 mg (13.0 microg versus 17.6 microg).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),μg,17.6,41081,DB01037,Selegiline
,17715422,absolute bioavailability,"Transdermal selegiline administration reduced metabolism and produced a high, sustained plasma selegiline concentration over the dosing period, with an absolute bioavailability of 73%.",Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17715422/),%,73,47879,DB01037,Selegiline
,17715422,absolute bioavailability,"By contrast, oral dosing produced a sharp plasma selegiline peak that occurred within 1 hour and declined rapidly, with an absolute bioavailability of 4%.",Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17715422/),%,4,47880,DB01037,Selegiline
,31058136,Extra,"Extraction recoveries ranged from 48.6 to 105.4% with coefficients of variation (CV) ≤ 13.7%, and matrix effects ranged from 45.4 to 104.1% with CV ≤ 10.3%.","Simultaneous Determination of Selegiline, Desmethylselegiline, R/S-methamphetamine, and R/S-amphetamine on Dried Urine Spots by LC/MS/MS: Application to a Pharmacokinetic Study in Urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058136/),%,48.6 to 105.4,52709,DB01037,Selegiline
,16485914,elimination half-life (t(1/2)),The elimination half-life (t(1/2)) of levodopa from plasma (in combination with a decarboxylase inhibitor) of about 1.5 hours becomes more influential as the disease progresses.,Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485914/),h,1.5,61864,DB01037,Selegiline
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.69,69883,DB01037,Selegiline
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.76,69884,DB01037,Selegiline
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.98,69885,DB01037,Selegiline
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.96,69886,DB01037,Selegiline
,20038213,permeation,The permeation of SH was very low by passive delivery (2.29 ± 0.05 µg/cm²/h) as compared to iontophoresis at 0.5 mA/cm² (65.10 ± 5.04 µg/cm²/h).,"Transdermal iontophoretic delivery of selegiline hydrochloride, in vitro. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20038213/),[μg] / [cm²·h],2.29,72182,DB01037,Selegiline
,20038213,permeation,The permeation of SH was very low by passive delivery (2.29 ± 0.05 µg/cm²/h) as compared to iontophoresis at 0.5 mA/cm² (65.10 ± 5.04 µg/cm²/h).,"Transdermal iontophoretic delivery of selegiline hydrochloride, in vitro. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20038213/),[μg] / [cm²·h],65.10,72183,DB01037,Selegiline
,20038213,maximum flux,"Overall, with 20 mg/mL SH and a current density of 0.4 mA/cm², a maximum flux of 305.5 µg/cm²/h was obtained.","Transdermal iontophoretic delivery of selegiline hydrochloride, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20038213/),[μg] / [cm²·h],305.5,72184,DB01037,Selegiline
,9797797,Peak serum concentrations,Peak serum concentrations of selegiline were reached rapidly and ranged from 1 to 32 nmol/L.,CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[nM] / [l],1 to 32,84693,DB01037,Selegiline
,9797797,50% inhibitory concentration,"The inhibitory potency of selegiline, desmethylselegiline, and l-methamphetamine toward dextromethorphan O-demethylase was very low (50% inhibitory concentration values from 160 to 580 mumol/L).",CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[μM] / [l],160 to 580,84694,DB01037,Selegiline
,30614204,initial detection time,"After oral administration, each analyte could be detected in OF specimens from all volunteers with an initial detection time of 0.50 hours.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,0.50,89117,DB01037,Selegiline
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],50.93-992.67,89118,DB01037,Selegiline
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],29.78-653.64,89119,DB01037,Selegiline
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],8.22-150.15,89120,DB01037,Selegiline
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],4.34-16.25,89121,DB01037,Selegiline
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,5-24,89122,DB01037,Selegiline
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,52-96,89123,DB01037,Selegiline
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,31-96,89124,DB01037,Selegiline
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,13-31,89125,DB01037,Selegiline
,7995016,half-life of recovery,"In rat brain the half-life of recovery in the brain is approximately 8 to 12 days; in rat liver it is shorter, 1 to 3 days.",Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995016/),d,8 to 12,114602,DB01037,Selegiline
,7995016,half-life of recovery,"In rat brain the half-life of recovery in the brain is approximately 8 to 12 days; in rat liver it is shorter, 1 to 3 days.",Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995016/),d,1 to 3,114603,DB01037,Selegiline
>,11862224,first-pass extraction,"The transdermal administration of SEL bypasses the first-pass metabolism, that is significant after oral administration (first-pass extraction >90%).",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),%,90,125181,DB01037,Selegiline
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],1.19,125182,DB01037,Selegiline
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],23.22,125183,DB01037,Selegiline
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],4.78,125184,DB01037,Selegiline
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],14.08,125185,DB01037,Selegiline
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],2.10,125186,DB01037,Selegiline
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],0.85,125187,DB01037,Selegiline
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],1.06,125188,DB01037,Selegiline
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],2.71,125189,DB01037,Selegiline
,30580084,detection limit,The method allowed accurate and precise determination of RSM in the linearity range 0.50-100 ng mL-1 with a detection limit of 0.16 ng mL-1 for RSM in rat plasma.,Dansyl azide as a selective fluorescence tagging probe for click chemistry reactions and its application to monitor rasagiline in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580084/),[ng] / [ml],0.16,132234,DB01037,Selegiline
,9260033,peak plasma concentration (Cmax),The mean peak plasma concentration (Cmax) is approximately 2 micrograms/L and the time to reach the peak is under an hour.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),[μg] / [l],2,136781,DB01037,Selegiline
under,9260033,time to reach the peak,The mean peak plasma concentration (Cmax) is approximately 2 micrograms/L and the time to reach the peak is under an hour.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),h,an,136782,DB01037,Selegiline
,9260033,absolute bioavailability,The absolute bioavailability of selegiline is approximately 10%.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),%,10,136783,DB01037,Selegiline
,9260033,apparent volume of distribution,It has an apparent volume of distribution of 1854 L.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),l,1854,136784,DB01037,Selegiline
,9260033,oral clearance,"The oral clearance of selegiline (59 L/min) is many fold higher than the liver blood flow (1.5 L/min), indicating that extrahepatic processes are involved in the elimination of selegiline.",Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),[l] / [min],59,136785,DB01037,Selegiline
,9260033,oral clearance,"The oral clearance of selegiline (59 L/min) is many fold higher than the liver blood flow (1.5 L/min), indicating that extrahepatic processes are involved in the elimination of selegiline.",Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),[l] / [min],1.5,136786,DB01037,Selegiline
,9260033,elimination half-life,The elimination half-life of selegiline is about 1.5 hours.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),h,1.5,136787,DB01037,Selegiline
,10682227,half-lives,"However, the half-lives of selegiline (range, 1.5-3.5 h) and desmethylselegiline (range, 3.4-5.3 h) were found to be relatively short.",Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682227/),h,1.5-3.5,143558,DB01037,Selegiline
,10682227,half-lives,"However, the half-lives of selegiline (range, 1.5-3.5 h) and desmethylselegiline (range, 3.4-5.3 h) were found to be relatively short.",Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682227/),h,3.4-5.3,143559,DB01037,Selegiline
< or =,17982891,t1/2beta,The peak concentrations (C(max)) were reached at 15 min after treatment and the absorption was followed by a fast elimination (t1/2beta < or = 2h).,Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982891/),h,2,146749,DB01037,Selegiline
,17982891,bioavailability,Increased bioavailability was detected after subcutaneous (87.1%) and intraperitoneal (78.7%) administration.,Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982891/),%,87.1,146750,DB01037,Selegiline
,17982891,bioavailability,Increased bioavailability was detected after subcutaneous (87.1%) and intraperitoneal (78.7%) administration.,Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982891/),%,78.7,146751,DB01037,Selegiline
,9243353,time to reach maximal inhibition [tmax],"The maximal inhibition by desmethylselegiline was reached significantly later after desmethylselegiline (time to reach maximal inhibition [tmax], 27 +/- 20 hours) than after selegiline administration (tmax, 1.4 +/- 1.4 hours).","Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243353/),h,27,149858,DB01037,Selegiline
,9243353,tmax,"The maximal inhibition by desmethylselegiline was reached significantly later after desmethylselegiline (time to reach maximal inhibition [tmax], 27 +/- 20 hours) than after selegiline administration (tmax, 1.4 +/- 1.4 hours).","Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243353/),h,1.4,149859,DB01037,Selegiline
,11862265,Trough levels,Trough levels of 3.3 and 6.0 ng / mL for L-amphetamine and L-methamphetamine suggest that steady state was achieved by the third dosing day for these metabolites.,"The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),[ng] / [ml],3.3,184467,DB01037,Selegiline
,11862265,Trough levels,Trough levels of 3.3 and 6.0 ng / mL for L-amphetamine and L-methamphetamine suggest that steady state was achieved by the third dosing day for these metabolites.,"The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),[ng] / [ml],6.0,184468,DB01037,Selegiline
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,8.6,184469,DB01037,Selegiline
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,9.5,184470,DB01037,Selegiline
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,1.5,184471,DB01037,Selegiline
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,3.8,184472,DB01037,Selegiline
,9331518,relative bioavailability,The relative bioavailability of selegiline was slightly reduced (by 29%; p = 0.008) when citalopram was coadministered compared with selegiline alone.,Lack of adverse interactions between concomitantly administered selegiline and citalopram. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331518/),,29,188189,DB01037,Selegiline
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],6.5,204252,DB01037,Selegiline
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],14.7,204253,DB01037,Selegiline
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],0.9,204254,DB01037,Selegiline
,2515726,recovery,"The metabolites of selegiline were excreted in urine, and the recovery as metabolites was 87%.",Pharmacokinetics and metabolism of selegiline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),%,87,204255,DB01037,Selegiline
,9021435,elimination half-life,"As plasma levels of selegiline are very low and the elimination half-life is very short being about 9 minutes, therefore, a very sensitive and selective method for determining the 3 main metabolites desmethylselegiline (DMS), methamphetamine (MA) and amphetamine (A) was developed.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),min,9,206451,DB01037,Selegiline
,9021435,Cmax,"After application of a single oral dose of 5 mg selegiline the Cmax values of DMS reached 5-6 ng/ml, of MA 6-7 ng/ml and of A about 2 ng/ml.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [ml],5-6,206452,DB01037,Selegiline
,9021435,Cmax,"After application of a single oral dose of 5 mg selegiline the Cmax values of DMS reached 5-6 ng/ml, of MA 6-7 ng/ml and of A about 2 ng/ml.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [ml],6-7,206453,DB01037,Selegiline
,9021435,Cmax,"After application of a single oral dose of 5 mg selegiline the Cmax values of DMS reached 5-6 ng/ml, of MA 6-7 ng/ml and of A about 2 ng/ml.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [ml],2,206454,DB01037,Selegiline
,9021435,AUC infinity,"The AUC infinity values were with DMS about 11 ng/ml x h +/- 4.5, with MA about 130 g/ml x h +/- 50 and with A about 50 ng/ml x h +/- 15.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [h·ml],11,206455,DB01037,Selegiline
,9021435,MA,"The AUC infinity values were with DMS about 11 ng/ml x h +/- 4.5, with MA about 130 g/ml x h +/- 50 and with A about 50 ng/ml x h +/- 15.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[g] / [h·ml],130,206456,DB01037,Selegiline
,9021435,A,"The AUC infinity values were with DMS about 11 ng/ml x h +/- 4.5, with MA about 130 g/ml x h +/- 50 and with A about 50 ng/ml x h +/- 15.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [h·ml],50,206457,DB01037,Selegiline
,12844325,elimination half-life,The elimination half-life of cabergoline estimated from urinary data of healthy subjects ranges between 63 and 109 hours.,Clinical pharmacokinetics of cabergoline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844325/),h,63 and 109,210629,DB01037,Selegiline
,28875405,highest flux,"In vitro studies indicated that components of nanoemulsion acted as permeation enhancers with highest flux of 3.531 ± 1.94 μg/cm2/h from nanoemulsion SB6 containing 0.5 mg selegiline hydrochloride, 3% distilled water, 21% S mix (Span 85, Tween 80, PEG 400), and 76% isopropyl myristate by weight.","Appraisal of Transdermal Water-in-Oil Nanoemulgel of Selegiline HCl for the Effective Management of Parkinson's Disease: Pharmacodynamic, Pharmacokinetic, and Biochemical Investigations. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28875405/),[μg] / [cm2·h],3.531,213107,DB01037,Selegiline
,28875405,polydispersity index,"SB6 with the least droplet size of 183.4 ± 0.35 nm, polydispersity index of 0.42 ± 0.06 with pH of 5.9 ± 0.32 and viscosity of 22.42 ± 0.14 cps was converted to nanoemulsion gel NEGS4 (viscosity = 22,200 ± 400 cps) by addition of Viscup160® for ease of application and evaluated for permeation, safety, and pharmacokinetic profile in Wistar rats.","Appraisal of Transdermal Water-in-Oil Nanoemulgel of Selegiline HCl for the Effective Management of Parkinson's Disease: Pharmacodynamic, Pharmacokinetic, and Biochemical Investigations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28875405/),,0.42,213108,DB01037,Selegiline
,28875405,viscosity,"SB6 with the least droplet size of 183.4 ± 0.35 nm, polydispersity index of 0.42 ± 0.06 with pH of 5.9 ± 0.32 and viscosity of 22.42 ± 0.14 cps was converted to nanoemulsion gel NEGS4 (viscosity = 22,200 ± 400 cps) by addition of Viscup160® for ease of application and evaluated for permeation, safety, and pharmacokinetic profile in Wistar rats.","Appraisal of Transdermal Water-in-Oil Nanoemulgel of Selegiline HCl for the Effective Management of Parkinson's Disease: Pharmacodynamic, Pharmacokinetic, and Biochemical Investigations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28875405/),cps,22.42,213109,DB01037,Selegiline
,28875405,viscosity,"SB6 with the least droplet size of 183.4 ± 0.35 nm, polydispersity index of 0.42 ± 0.06 with pH of 5.9 ± 0.32 and viscosity of 22.42 ± 0.14 cps was converted to nanoemulsion gel NEGS4 (viscosity = 22,200 ± 400 cps) by addition of Viscup160® for ease of application and evaluated for permeation, safety, and pharmacokinetic profile in Wistar rats.","Appraisal of Transdermal Water-in-Oil Nanoemulgel of Selegiline HCl for the Effective Management of Parkinson's Disease: Pharmacodynamic, Pharmacokinetic, and Biochemical Investigations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28875405/),cps,"22,200",213110,DB01037,Selegiline
>,29717617,Brain:blood ratio,"Brain:blood ratio of 2.207 > 0.093 of selegiline-loaded nanoemulsion (intranasally administered) > selegiline solution (administered intravenously), respectively, at 0.5 hours showed direct nose-to-brain delivery of drug bypassing blood-brain barrier.",Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717617/),,2.207,214678,DB01037,Selegiline
>,29717617,Brain:blood ratio,"Brain:blood ratio of 2.207 > 0.093 of selegiline-loaded nanoemulsion (intranasally administered) > selegiline solution (administered intravenously), respectively, at 0.5 hours showed direct nose-to-brain delivery of drug bypassing blood-brain barrier.",Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717617/),,0.093,214679,DB01037,Selegiline
,32175515,oral bioavailability,"The pharmacokinetic results demonstrated that the oral bioavailability of selegiline alone was approximately 18%; however, when rats were pretreated with low and high doses of the ginseng extract, the bioavailability of selegiline was 7.2 and 29%, respectively.",Preclinical Herb-Drug Pharmacokinetic Interaction of Panax ginseng Extract and Selegiline in Freely Moving Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32175515/),%,18,218615,DB01037,Selegiline
,32175515,bioavailability,"The pharmacokinetic results demonstrated that the oral bioavailability of selegiline alone was approximately 18%; however, when rats were pretreated with low and high doses of the ginseng extract, the bioavailability of selegiline was 7.2 and 29%, respectively.",Preclinical Herb-Drug Pharmacokinetic Interaction of Panax ginseng Extract and Selegiline in Freely Moving Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32175515/),%,7.2,218616,DB01037,Selegiline
,32175515,bioavailability,"The pharmacokinetic results demonstrated that the oral bioavailability of selegiline alone was approximately 18%; however, when rats were pretreated with low and high doses of the ginseng extract, the bioavailability of selegiline was 7.2 and 29%, respectively.",Preclinical Herb-Drug Pharmacokinetic Interaction of Panax ginseng Extract and Selegiline in Freely Moving Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32175515/),%,29,218617,DB01037,Selegiline
>,33557601,folding,"The film F2 demonstrated satisfactory weight (10.60 mg), folding endurance (>200), drug content (11.44 mg/cm2), disintegration time (68 s), mucoadhesive strength (47.7 N/cm2), and controlled release for 30 min.",Development and characterization of sublingual films for enhanced bioavailability of selegiline hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33557601/),,200,222762,DB01037,Selegiline
,33557601,disintegration time,"The film F2 demonstrated satisfactory weight (10.60 mg), folding endurance (>200), drug content (11.44 mg/cm2), disintegration time (68 s), mucoadhesive strength (47.7 N/cm2), and controlled release for 30 min.",Development and characterization of sublingual films for enhanced bioavailability of selegiline hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33557601/),s,68,222763,DB01037,Selegiline
,18065502,AUC,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ng] / [h·ml],90.7,258469,DB01037,Selegiline
,18065502,AUC,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ng] / [h·ml],57.4,258470,DB01037,Selegiline
,18065502,clearance,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ml] / [min],4.6,258471,DB01037,Selegiline
,18065502,clearance,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ml] / [min],7.3,258472,DB01037,Selegiline
,18065502,elimination half-life,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),min,12.5,258473,DB01037,Selegiline
,18065502,elimination half-life,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),min,6.6,258474,DB01037,Selegiline
,18065502,K(i),Selegiline preincubation increased inhibition in microsomes (3.7-fold) and CYP2A6 (14.8-fold); the K(i) for CYP2A6 was 4.2 muM.,Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),muM,4.2,258475,DB01037,Selegiline
,18065502,K(i),"Selegiline dose- and time-dependently inhibited nicotine metabolism by CYP2A6 (K(i) = 15.6 +/- 2.7 muM; k(inact) = 0.34 +/- 0.04 min(-1)), and the inhibition was irreversible in the presence of NADPH, indicating that it is a mechanism-based inhibitor of CYP2A6.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),muM,15.6,258476,DB01037,Selegiline
,18065502,k(inact),"Selegiline dose- and time-dependently inhibited nicotine metabolism by CYP2A6 (K(i) = 15.6 +/- 2.7 muM; k(inact) = 0.34 +/- 0.04 min(-1)), and the inhibition was irreversible in the presence of NADPH, indicating that it is a mechanism-based inhibitor of CYP2A6.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),1/[min],0.34,258477,DB01037,Selegiline
,7888597,terminal half-life,"The mean terminal half-life, volume of distribution of the central compartment, and systemic clearance of selegiline were 60.24 +/- 9.56 min, 6.56 +/- 0.56 L kg-1, and 159.91 +/- 19.28 mL min-1 kg-1, respectively.",The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),min,60.24,259906,DB01037,Selegiline
,7888597,volume of distribution of the central compartment,"The mean terminal half-life, volume of distribution of the central compartment, and systemic clearance of selegiline were 60.24 +/- 9.56 min, 6.56 +/- 0.56 L kg-1, and 159.91 +/- 19.28 mL min-1 kg-1, respectively.",The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),[l] / [kg],6.56,259907,DB01037,Selegiline
,7888597,systemic clearance,"The mean terminal half-life, volume of distribution of the central compartment, and systemic clearance of selegiline were 60.24 +/- 9.56 min, 6.56 +/- 0.56 L kg-1, and 159.91 +/- 19.28 mL min-1 kg-1, respectively.",The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),[ml] / [kg·min],159.91,259908,DB01037,Selegiline
,7888597,tmax,"After oral administration selegiline appeared to be absorbed rapidly with a tmax and Cmax of 25 +/- 5.8 min and 5.2 +/- 1.36 ng mL-1, respectively.",The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),min,25,259909,DB01037,Selegiline
,7888597,Cmax,"After oral administration selegiline appeared to be absorbed rapidly with a tmax and Cmax of 25 +/- 5.8 min and 5.2 +/- 1.36 ng mL-1, respectively.",The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),[ng] / [ml],5.2,259910,DB01037,Selegiline
,7888597,absolute bioavailability,The absolute bioavailability of selegiline in the dog was 8.51 +/- 3.31%.,The pharmacokinetics and absolute bioavailability of selegiline in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888597/),%,8.51,259911,DB01037,Selegiline
,16413604,elimination half-life,"The elimination half-life of methamphetamine was approximately 12 h, and selegiline did not alter clearance of methamphetamine.",A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413604/),h,12,265657,DB01037,Selegiline
,9373724,ratio of formation-absorption rate constant,"Compartmental analysis indicates that the ratio of formation-absorption rate constant for the selegiline to N-desmethylselegiline pathway decreases from 1.57 +/- 1.04 for the first pulse to 0.61 +/- 0.54 for the second pulse of the pulsatile delivery system, suggesting that the upper portion of the GI tract has a greater capacity to convert selegiline to N-desmethylselegiline than the lower GI tract.",Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373724/),,1.57,269039,DB01037,Selegiline
,9373724,ratio of formation-absorption rate constant,"Compartmental analysis indicates that the ratio of formation-absorption rate constant for the selegiline to N-desmethylselegiline pathway decreases from 1.57 +/- 1.04 for the first pulse to 0.61 +/- 0.54 for the second pulse of the pulsatile delivery system, suggesting that the upper portion of the GI tract has a greater capacity to convert selegiline to N-desmethylselegiline than the lower GI tract.",Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373724/),,0.61,269040,DB01037,Selegiline
